Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 3/20 | 0.35 |
| ▸ | CNR1 | P21554 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11221046 | 0.82 | GAA (0.44) | GAATSHRPOLBCYP3A4MAPT | |
| SCHEMBL11367271 | 0.81 | GAA (0.43) | GAATSHRPOLBCYP3A4MAPT | |
| SCHEMBL16594895 | 0.81 | GAA (0.43) | GAATSHRPOLBCYP3A4MAPT | |
| SCHEMBL27096133 | 0.79 | GAA (0.42) | GAATSHRPOLBCYP3A4MAPT | |
| SCHEMBL7518193 | 0.77 | PLA2G7 (0.50) | PLA2G7POLBMMP2MMP1 | |
| SCHEMBL11081294 | 0.77 | POLB (0.35) | GAATSHRPOLBL3MBTL1ALDH1A1 | |
| SCHEMBL537187 | 0.76 | POLB (0.37) | GAATSHRPOLBMAPTL3MBTL1 | |
| SCHEMBL15974512 | 0.74 | POLB (0.39) | GAATSHRPOLBMAPTL3MBTL1 | |
| SCHEMBL13597773 | 0.74 | POLB (0.33) | GAATSHRPOLBL3MBTL1 | |
| SCHEMBL13597776 | 0.74 | POLB (0.33) | GAATSHRPOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008045671-A1 | MATRIX METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-17 | — | — | WO | claimed |
| WO-2008045671-A1 | MATRIX METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-17 | — | — | WO | disclosed |
| EP-1001930-B1 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LAB (US) | 2002-12-04 | — | — | EP | disclosed |
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | DAVIDSEN STEVEN K (US) | 2002-01-17 | — | — | US | disclosed |
| US-6294573-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION | ABBOTT LABORATORIES | 2001-09-25 | — | — | US | disclosed |
| US-6235786-B1 | RHEUMATIC DISORDERS; BONE DISORDERS; ORAL DISEASES; ANTIULCER AGENTS; ANTITUMOR AGENTS | ABBOTT LABORATORIES | 2001-05-22 | — | — | US | disclosed |
| EP-1001930-A2 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | Abbott Laboratories (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006361-A2 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | MMP1, MMP9, MMP3 | GAA 259/4885TSHR 3628/4885PLA2G7 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.